Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY: NVO )

77.87 -0.96 (-1.22%)
Official Closing Price Updated: 7:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
72 73 Next >
Where Will Madrigal Pharmaceuticals Be in 3 Years?
The coast is clear for it to grow, for now. 
Via The Motley Fool
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Want peace of mind about your investments? Consider these great stocks. 
Via The Motley Fool
$100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today
Via Benzinga
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
The company just unveiled preclinical results from a test of its GLP-1 weight-loss drug. 
Via Investor's Business Daily
7 A-Rated Biotech Stocks Worth Betting on in June
A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation. 
Via InvestorPlace
3 Stocks to Sell as Ozempic Surges in Popularity
GLP-1s are a weight-loss breakthrough, but these three stocks to sell have a lot to lose from their rapid rise in popularity. 
Via InvestorPlace
Novo Nordisk Unusual Options Activity For June 13
Via Benzinga
6 Analysts Have This To Say About Novo Nordisk
Via Benzinga
Got $200? 2 Healthcare Stocks to Buy and Hold Forever.
They aren't the flashiest stocks, but they get the job done. 
Via The Motley Fool
Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug
Novo Nordisk's competition in the obesity drug market is heating up. 
Via The Motley Fool
Weight Loss Drugs: Are They Really Magic?
Talking about weight and weight loss with Johann Hari, an Ozempic user and the author of "Magic Pill: The Extraordinary Benefits and Disturbing Risks of the New Weight-Loss Drugs." 
Via The Motley Fool
JPMorgan's $500M Venture Capital Fund Bets Big On Weight-Loss Drugs: 'They're All The Rage'
JPMorgan's $500M venture capital fund dives into weight-loss craze, eyeing potential market upheaval in pharmaceuticals. 
Via Benzinga
3 Stocks to Buy as Ozempic Surges in Popularity
Ozempic has surged in popularity in recent years, but the best may be to come as innovators look to launch new drugs to meet hot demand. 
Via InvestorPlace
Ozempic Maker Novo Nordisk Closes In On Lego As Denmark's Most Valuable Brand: Report
Novo Nordisk is challenging Lego A/S for the title of Denmark's most valuable brand, with its brand value surging 59% to $5.1 billion. This growth is fueled by the global popularity of its weight-loss... 
Via Benzinga
Humans Clamor For Weight Loss Drugs, But The Next Users Could Be... Pets?
Could GLP-1 drugs for weight loss in pets be the next big thing? Success of Novo Nordisk and Eli Lilly in human market could pave the way. 
Via Benzinga
7 Trending Stocks With Momentum on Their Side
Trending stocks offer an opportunity to ride momentum higher and create quick returns for daring investors. 
Via InvestorPlace
Is Eli Lilly the Best Pharmaceutical Stock for You?
Eli Lilly is serving a market that may reach $100 billion. 
Via The Motley Fool
Jim Cramer Sees Eli Lilly As More Than A 'One-Trick Pony' After FDA Advisors Back Its Alzheimer's Drug: 'It's Ultimately Headed To A Trillion Dollar Valuation'
Jim Cramer has expressed his confidence in Eli Lilly and Co, citing the company's diverse drug portfolio and the recent endorsement of its Alzheimer's treatment by FDA advisors. 
Via Benzinga
Exposures Product Safety
Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?
Analysts who follow the start-up drugmaker think its stock has a chance to soar, but that doesn't mean it's right for you. 
Via The Motley Fool
Meet The International Megacaps That 'Match Or Surpass' Magnificent Seven Stocks
Five mega companies may offer higher earnings and return potential with lower risk. 
Via Investor's Business Daily
Abbott Snags U.S. Clearance To Enter The Obesity Arena, Rivaling Dexcom
The FDA clearance for two new CGMs puts Abbott on track to rival Dexcom's new Stelo device. 
Via Investor's Business Daily
Exposures Product Safety
The Safety Net Seven: 7 Stocks to Own for Unshakeable Returns
Although they’re not necessarily the most exciting ideas, investors should turn to safe stocks to buy to manage the market’s ambiguity. 
Via InvestorPlace
Week Of June 9: What's In Store For The Markets
The stock market is very similar to the rest of the economy with winners and losers, but many more losers. Many of today’s high-flyers will be unknown ten years from now. 
Via Talk Markets
Topics Economy
Exposures Economy
Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?
Structure Therapeutics has a long way to go before beating Wegovy. 
Via The Motley Fool
Here's Why Demand for Ozempic and Wegovy Could Soar Even Higher
Novo Nordisk's stock may not look all that expensive when you're focusing on the long-term potential. 
Via The Motley Fool
Profiting from the Crowd: 3 Stocks Set to Surge on Retail Investor Enthusiasm
You can use the wisdom of crowds and their fear and greed motives to profit from these three stocks to buy with plenty of room to run. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Over 10,000 Lawsuits In Novo Nordisk's Ozempic Case Assigned to New Judge
Judge Karen Marston takes over the high-profile Ozempic litigation involving over 10,000 lawsuits. Here's the latest. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential
New ETFs focusing on weight-loss drugs have launched. However, industry observers caution about their long-term prospects and the concentrated risks associated with these investments. 
Via Benzinga
Topics ETFs
Ozempic, Wegovy Create Domino Effect As New Products Emerge Across Industries To Capture New Consumer Habits
Companies from food and beverage to fitness are adapting to the increased demand for these drugs, hoping to capitalize on shifting consumer habits 
Via Benzinga
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
72 73 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.